Industry's Drug Pricing Power Is Running On Fumes
Pharma is facing a big headwind in 2019 in the form of diminished drug pricing power. The pricing trend puts net drug prices squarely in the red for most large pharma manufacturers, but US lawmakers aren't likely to be reassured heading into an upcoming hearing on drug pricing.
You may also be interested in...
Median out-of-pocket and insurance costs for 49 high-volume brand-name drugs jumped 79% from 2012 to 2017 in a new analysis of 35m individual insurance claims published in JAMA Network. Competition did not correlate to lower costs.
Net price growth of 0.3% for branded drugs in 2018 was 1.6% below Consumer Price Index inflation, while invoice prices grew an average of 5.5%.
Trulicity, Taltz grew in the first quarter, but below analyst consensus estimates. Company points to price decreases as holding down growth.